The Latest Cardiac and Vascular News
BASKING RIDGE, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and six months ended June 30, 2018 after […]
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report second quarter 2018 financial and operating results on Wednesday, August 8, 2018. Management will […]
ANN ARBOR, Mich., Aug. 02, 2018 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates and financial results for […]
LAS VEGAS, Aug. 2, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. […]
PORTLAND, Ore.–(BUSINESS WIRE)–VisCardia Inc., a privately held medical device developer, announced today the first implant of the VisONE® implantable system for heart failure, and the commencement of its VisONE Heart Failure pilot study in Ukraine. The VisONE implantable system delivers VisCardia’s proprietary Asymptomatic Diaphragmatic Stimulation (ADS) therapy to improve cardiac […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–BioAxone BioSciences, Inc., a biotechnology company focused on developing innovative drugs to treat neurotrauma and neurovascular disorders today announced that CEO Lisa McKerracher, PhD, will be a platform speaker on the Scientific Program, “Update on Clinical Trials in SCI” at NeuroTrauma2018, The 3rd Joint Symposium of the International and National […]
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $10 million milestone payment from Amgen following the administration of the first dose of AMG 890, formerly referred to as ARO-LPA, in a clinical study. Amgen is evaluating AMG 890 in a Phase 1 clinical study […]
Santa Monica, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced that it has applied to list the Company’s common stock on […]
BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2018, and provided an update on company operations. Key […]
TEL AVIV, Israel, Aug. 1, 2018 /PRNewswire/ — Vascular Graft Solutions announces today that John Radcliffe hospital in Oxford, is the first center in the UK to use its VEST technology to externally support vein grafts in patients undergoing coronary bypass surgery. “After several decades in which little progress had been made in coronary […]
